Open AccessBiosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
Author(s) -
Yunpeng Yang,
Bin Wu,
Lingxia Huang,
Min Shi,
Yunpeng Liu,
Yanqiu Zhao,
Lijun Wang,
Shun Lü,
Gongyan Chen,
Baolan Li,
Conghua Xie,
Jian Fang,
g Yang,
Yiping Zhang,
Jiuwei Cui,
Yong Song,
Cuiying Zhang,
Xiaodong Mei,
Bangwei Cao,
Lan Yang,
Ying Cheng,
Kejing Ying,
Tao Sun,
Bin Ren,
Qitao Yu,
Zhijun Liao,
ZhiJun Pei,
Mengzhao Wang,
Jianying Zhou,
Shiying Yu,
Guosheng Feng,
Huiping Wan,
Huaqing Wang,
Shegan Gao,
Jinliang Wang,
Guangyu An,
Yayuan Geng,
Yanxia Ji,
Ying Yuan,
Shenglin Ma,
Zhongyao Jia,
Mu Hu,
Hui Zhou,
Jie Yu,
Xiaofeng Sun,
Li Zhang
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.12.23
Subject(s) - bevacizumab , medicine , carboplatin , lung cancer , oncology , clinical endpoint , paclitaxel , adverse effect , vascular endothelial growth factor , chemotherapy , randomized controlled trial , cisplatin , vegf receptors
Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients.